Today: 28 June 2026
Browse Category

NASDAQ:VKTX 26 September 2025 - 23 June 2026

Viking Therapeutics Stock Jumps as Obesity Drug Catalyst Nears

Viking Therapeutics Stock Jumps as Obesity Drug Catalyst Nears

Viking Therapeutics surged 6% to $34.30 as investors bet on Phase 3 data for its lead obesity drug VK2735, expected in Q3 2026, despite no new company news and a broader market selloff; the stock’s rally reflects hopes for a late-stage win in a fiercely competitive $100 billion market dominated by Novo Nordisk and Eli Lilly, but Viking warns that delays or weak results could hit shares.
23 June 2026
··
Viking Therapeutics stock (VKTX) slips in premarket after 11% rally as Novo obesity-drug stumble hits tape

Viking Therapeutics stock (VKTX) slips in premarket after 11% rally as Novo obesity-drug stumble hits tape

Viking Therapeutics shares fell 0.5% to $34.30 in premarket trading Tuesday after an 11.1% surge Monday, as investors reacted to new obesity drug trial data from Novo Nordisk. Novo’s CagriSema showed less weight loss than Eli Lilly’s rival drug, shaking the sector. Viking plans to advance its oral obesity drug VK2735 into late-stage trials in Q3. Investors await updates at upcoming healthcare conferences in March and April.
24 February 2026
··
Structure Therapeutics stock jumps as Novo deal talk lifts obesity-drug names

Structure Therapeutics stock jumps as Novo deal talk lifts obesity-drug names

Structure Therapeutics (GPCR) shares surged 7.5% to $83.76 Wednesday on over 1 million shares traded, fueled by buyout speculation and renewed interest in oral obesity drugs. Novo Nordisk executives signaled openness to acquisitions, while Structure reported Phase 2b data showing its oral GLP-1 drug aleniglipron led to 11.3% placebo-adjusted weight loss at 36 weeks. Viking Therapeutics and Terns Pharmaceuticals also rose sharply.
14 January 2026
······
Viking Therapeutics stock jumps 11% as CEO flags broader appetite for obesity-drug deals

Viking Therapeutics stock jumps 11% as CEO flags broader appetite for obesity-drug deals

Viking Therapeutics shares surged about 11% to $34.06 by early afternoon Wednesday amid renewed speculation of a deal in obesity drugs. CEO Brian Lian said more companies are “circling around the space” at the J.P. Morgan healthcare conference. Viking reported Phase 2 trial data for VK2735 showing up to 14.7% weight loss after 13 weeks. No official deals have been announced.
14 January 2026
·
Pfizer stock slips as CEO says obesity cash-pay market is “almost like Viagra”

Pfizer stock slips as CEO says obesity cash-pay market is “almost like Viagra”

Pfizer shares fell 0.7% to $25.10 Tuesday after CEO Albert Bourla told the J.P. Morgan Healthcare Conference the cash-pay obesity market is larger than expected. Pfizer plans 10 phase 3 trials for its Metsera drugs by end-2026 but does not expect revenue growth until 2029. Investors await Feb. 3 results for updates on the obesity pipeline and 2026 strategy. Rival Novo Nordisk launched a daily oral Wegovy in the U.S. this month.
13 January 2026
····
Viking Therapeutics stock sinks as Novo’s Wegovy pill debut resets obesity-drug pricing

Viking Therapeutics stock sinks as Novo’s Wegovy pill debut resets obesity-drug pricing

Viking Therapeutics shares fell 9.9% to $31.93 Monday after Novo Nordisk launched its Wegovy weight-loss pill in the U.S. with starter doses priced at $149 per month for cash-pay patients. Novo’s U.S.-listed shares rose 5.1%, while Eli Lilly dropped 3.9%. Viking’s next updates include Phase 3 trial milestones in Q1 and an earnings release expected Feb. 4.
5 January 2026
·····
Structure Therapeutics stock slides nearly 8% as Novo’s Wegovy pill debut jolts oral obesity-drug bets

Structure Therapeutics stock slides nearly 8% as Novo’s Wegovy pill debut jolts oral obesity-drug bets

Structure Therapeutics shares fell 7.7% to $62.86 after Novo Nordisk began U.S. sales of its Wegovy pill at $149 a month for self-paying patients. Structure’s stock had reached $72.02 earlier in the session before retreating. Investors await updates on its Phase 3 plans and next earnings report, expected Feb. 26.
5 January 2026
·····
Biggest Stock Losers Today: LEGN, MRVL, UL and More Slide as Wall Street Braces for a Fed Rate Cut (December 8, 2025)

Biggest Stock Losers Today: LEGN, MRVL, UL and More Slide as Wall Street Braces for a Fed Rate Cut (December 8, 2025)

Legend Biotech fell 12.8% to a new 52-week low Monday, leading U.S. stock declines as the S&P 500 hovered just below record highs ahead of the Fed’s rate decision. Marvell Technology dropped 8.6%, Unilever ADR lost 7%, and several others slid 4–6%. Traders priced in an 85–90% chance of a 25-basis-point Fed rate cut this week.
8 December 2025
············
VKTX Stock Forecast 2025–2026: Can Viking Therapeutics’ Obesity Drug Pipeline Really Double the Share Price?

VKTX Stock Forecast 2025–2026: Can Viking Therapeutics’ Obesity Drug Pipeline Really Double the Share Price?

Viking Therapeutics shares closed at $38.55 on December 5, 2025, with a market cap near $4.4 billion and analyst targets in the $80–$100 range. The stock is down 27% from its 52-week high but up 34% over three months, driven by late-stage obesity drug trials. Short interest stands at 22–24%. VK2735, its lead obesity candidate, remains in advanced development.
7 December 2025
··
VKTX Stock Today, November 25, 2025: Can Viking Therapeutics Keep Riding the Obesity Drug Wave?

VKTX Stock Today, November 25, 2025: Can Viking Therapeutics Keep Riding the Obesity Drug Wave?

Viking Therapeutics closed at $34.65 on November 24, valuing the company at about $3.9 billion. The firm completed enrollment in its Phase 3 obesity trial VANQUISH-1 ahead of schedule, with its lead drug VK2735 now in late-stage testing. Shares remain volatile, trading far below their 52-week high of $56.25 but well above the low of $18.92. Viking has no approved products or product revenue.
25 November 2025
··
Viking Therapeutics (VKTX) Pops as Canaccord Nudges Price Target to $107; Stifel Conference Buzz & Fresh ObesityWeek® Data — Nov. 12, 2025

Viking Therapeutics (VKTX) Pops as Canaccord Nudges Price Target to $107; Stifel Conference Buzz & Fresh ObesityWeek® Data — Nov. 12, 2025

Canaccord Genuity raised its Viking Therapeutics (VKTX) price target to $107, maintaining a Buy rating amid ongoing investor focus on obesity drug data. VKTX shares traded near $40 intraday as management appeared at the Stifel Healthcare Conference. Recent VENTURE trial results showed VK2735 led to 78% of prediabetics reaching normoglycemia, compared to 29% with placebo.
12 November 2025
·
Viking Therapeutics (VKTX) Rides Obesity Drug Wave: Stock Steadies as Analysts Eye Big Upside

Viking Therapeutics (VKTX) on Nov. 11, 2025: Stifel Fireside Chat Today, Fresh VK2735 Obesity Data From ObesityWeek, and Phase 3 VANQUISH Progress

Viking Therapeutics will hold a fireside chat today at the Stifel 2025 Healthcare Conference in New York, following new Phase 2 data showing VK2735 improved cardiometabolic measures in obesity patients. The company expects to complete enrollment for its Phase 3 VANQUISH‑1 trial by year-end, with VANQUISH‑2 to follow in early 2026. Viking reported a strong cash position and increased R&D spending in its Q3 update.
11 November 2025
Viking Therapeutics (VKTX) Today — Nov 9, 2025: New Institutional Buying, Fresh Technical Levels, and Key Catalysts Ahead

Viking Therapeutics (VKTX) Today — Nov 9, 2025: New Institutional Buying, Fresh Technical Levels, and Key Catalysts Ahead

Ethos Financial Group disclosed a new stake in Viking Therapeutics, acquiring 10,548 VKTX shares valued at about $280,000. VKTX closed Friday at $36.77 on volume of 4.65 million. Recent insider sales totaled 111,359 shares, while institutional ownership stands near 76%. Clinical updates include positive VK2735 obesity data and ongoing Phase 3 enrollment.
9 November 2025
·
Viking Therapeutics (VKTX) Rides Obesity Drug Wave: Stock Steadies as Analysts Eye Big Upside

Viking Therapeutics (VKTX) Rides Obesity Drug Wave: Stock Steadies as Analysts Eye Big Upside

Viking Therapeutics shares closed at $33.53 Friday, near recent highs after rebounding from a 40% drop in August. Its obesity drug VK2735 showed 12.2% weight loss in a Phase 2 trial but had a 20% dropout rate from side effects. Analysts see Viking as a possible acquisition target amid recent industry deals. The company holds over $800 million in cash and reports Q3 earnings on Oct. 22.
19 October 2025
··
Wall Street Rebounds: PCE In‑Line, Tariff Shock, and Fed‑Cut Bets — What It All Means (Sept. 26, 2025)

Wall Street Rebounds: PCE In‑Line, Tariff Shock, and Fed‑Cut Bets — What It All Means (Sept. 26, 2025)

U.S. inflation matched forecasts in August, with PCE up 0.3% from July and 2.7% year-on-year. Stocks rebounded, the S&P 500 and Dow rising about 0.5% by early afternoon. The White House announced new tariffs on drug imports, trucks, and furniture, effective Oct. 1. Treasury yields slipped, with the 10-year near 4.18% after the data release.
26 September 2025
·······

Stock Market Today

  • Bitcoin Hard Fork to Airdrop eCash in August; Soft Fork Faces Doubts
    June 28, 2026, 3:23 PM EDT. Bitcoin holders will receive free eCash coins via a hard fork scheduled for August 21, marking one of the few notable Bitcoin network splits in recent years. The eCash fork implements the Drivechain proposal, a concept allowing bitcoin movement into separate blockchains with different rules. Despite a decade of advocacy by Drivechain creator Paul Sztorc, the proposal lacks broad consensus due to legal risks and concerns over Bitcoin's core structure. This summer's forks contrast sharply with the contentious block size debates of 2017-2018 that produced Bitcoin Cash and Bitcoin SV. Another attempted soft fork in 2026 appears unlikely to succeed amid limited community support. These developments underline ongoing, albeit less polarized, debates over Bitcoin's technical future and governance.

Latest articles

UiPath (NYSE:PATH) shares see heavy trading after Friday’s jump as buyback calculations come into focus

UiPath (NYSE:PATH) shares see heavy trading after Friday’s jump as buyback calculations come into focus

28 June 2026
UiPath closed up 6.04% at $10.53 Friday, with weekly trading volume equal to 57% of its diluted share count, but shares remain 8.2% below the company’s average first-quarter buyback price of $11.47; with $500 million authorized for repurchases, every $100 million at current prices retires more shares, making buyback efficiency a key factor as revenue and ARR growth remain in the low-teens.
Go toTop